MTPVY yields 10.16% · JNJ yields 2.13%● Live data
📍 MTPVY pulled ahead of the other in Year 1
Combined, MTPVY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MTPVY + JNJ for your $10,000?
Métropole Télévision S.A. provides a range of programs, products, and services on various media. It operates through four segments: Television, Radio, Production and Audiovisual Rights, and Diversification. The company operates free-to-air channels, including M6, W9, 6TER, and Gulli; pay channels, such as Paris Première, Téva, sérieclub, Canal J, Tiji, M6 Music, MCM, MCM Top, and RFM TV; on-demand televisions comprising 6play, Gulli Max, and Gulli Replay; and advertising agency, as well as produces news magazines comprising Capital, Zone Interdite, Enquête Exclusive, 66 Minutes, and Enquêtes criminelles for W9. It also operates radio stations that include RTL, RTL2, and Fun Radio; distributes audiovisual film rights; and produces and co-produces films. In addition, the company engages in the TV channel broadcasting business; production, co-production, or co-distribution of short and long-playing formats, which comprise singles and albums, as well as compilations on physical and digital formats; and events and shows, including concerts, stand-up comedians, music shows, exhibitions, etc. Further, it engages in the program production, digital production and publishing, merchandising rights exploitation, estate agency, animated feature films production, Internet content and access provision, print publications, and teleshopping program activities. It also provides training and wholesale trade services; sells house; and develops cinematographic works. Métropole Télévision S.A. was incorporated in 1986 and is headquartered in Neuilly-sur-Seine, France.
Full MTPVY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.